Hasan ATBİNİCİ, SERKAN SİPAHİOĞLU, Nurten AKSOY, İslam BAYKARA, Uğur Erdem IŞIKAN

Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients

Objective: This study aimed to evaluate the effects of salmon calcitonin, and calcium and vitamin D treatment on bone mineral density, serum and synovial fluid bone formation and resorption markers in patients with osteoporosis.Methods: The study was completed with twenty-five osteoporosis patients divided into two groups: The 15 patients comprising Group I (1 male and 14 females; mean age: 67.0±12.0) were administered calcitonin treatment in addition to calcium and vitamin D. The 10 patients in Group II (3 males and 7 females; mean age 68.0±16.0) were administered calcium and vitamin D only. Serum and synovial fluid calcium phosphorus, alkaline phosphatase, calcitonin, C-telopeptide (CTx), N-telopeptide (NTx) and sialoprotein levels, and bone densitometries were determined at the beginning and at the end of one year of treatment.Results: In the calcitonin and calcium and vitamin D treatment group (Group I), femoral neck density scores were decreased and vertebrae scores were increased after one-year treatment. Both scores were increased in the non-calcitonin group (Group II). In Group I, synovial fluid levels of calcitonin, sialoprotein and NTx were decreased, and synovial fluid CTx levels showed no change. The only decrease that was statistically significant was that in calcitonin levels. In Group II, synovial fluid calcitonin levels were decreased, synovial fluid CTx levels were increased and synovial fluid NTx and sialoprotein level were unchanged. These changes were not statistically significant. Serum changes in the parameters were not statistically significant in either group.Conclusion: In osteoporosis, salmon calcitonin treatment affects synovial fluid bone formation and absorption marker levels. Advanced studies are needed to evaluate the mechanisms by which this takes place, and to explain the relationship between osteoporosis and articular cartilage metabolism

___

Miller PD, Zapalovski C. Bone mineral density measure- ments. In: Henderson JE, Goltzman D, editors. The osteo- porosis primer. Cambridge; New York: Cambridge Univer- sity Press; 2004. p. 262-77.

Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23.

Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, et al. Adherence to treatment of osteoporo- sis: a need for study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporo- sis Foundation of the USA. 2007;18:1311-7.

Christiansen C, Lindsay R. Estrogens, bone loss and pres- ervation. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Founda- tion of the USA. 1990;1:7-13.

Faulkner KG, McClung MR. Quality control of DXA in- struments in multicenter trials. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1995;5:218-27.

Leggate J, Farish E, Fletcher CD, McIntosh W, Hart DM, Sommerville JM. Calcitonin and postmenopausal osteopo- rosis. Clin Endocrinol (Oxf ) 1984;20:85-92.

Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Os- teoporosis international: a journal established as result of cooperation between the European Foundation for Osteo- porosis and the National Osteoporosis Foundation of the USA. 2000;11 Suppl 6:66-76.

Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporo- sis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2000;11 Suppl 6:2-17.

Taguchi Y, Gorai I, Zhang MG, Chaki O, Nakayama M, Minaguchi H. Differences in bone resorption after meno- pause in Japanese women with normal or low bone mineral density: quantitation of urinary cross-linked N-telopep- tides. Calcif Tissue Int 1998;62:395-9.

Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteo- porotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.

Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.

Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by mag- netic resonance imaging: results from the QUEST study. J Bone Miner Res 2005;20:1548-61.

Overgaard K, Riis BJ, Christiansen C, Pİdenphant J, Jo- hansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf ) 1989;30:435-42.

Hejdova M, Palicka V, Kucera Z, Vlcek J. Effects of alen- dronate and calcitonin on bone mineral density in post- menopausal osteoporotic women. An observational study. Pharm World Sci 2005;27:149-53.

Stock JL, Avioli LV, Baylink DJ, Chesnut C, Genant HK, Maricic MJ, et al. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three year interim results of the PROOF study. Bone Miner Res 1997;12.

Silverman SL. Calcitonin. Endocrinol Metab Clin North Am 2003;32:273-84.

Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, et al. Analgesic effect of salm- on calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospec- tive double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999;15:284-9.

Blau LA, Hoehns JD. Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 2003;37:564- 70.

Colpan L, Gur A, Cevik R, Nas K, Sarac AJ. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. Maturitas 2005;51:246-53.

Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ. Acute effects of calcitonin nasal spray on se- rum C-telopeptide of type 1 collagen (CTx) levels in elder- ly osteopenic women with increased bone turnover. Calcif Tissue Int 2004;75:477-81.

Trovas GP, Lyritis GP, Galanos A, Raptou P, Constante- lou E. A randomized trial of nasal spray salmon calcito- nin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002;17:521-7.

Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G. Early effect of nasal salmon cal- citonin on the bone marker Crosslaps. Rheumatol Int 2006;26:288-91.

Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral frac- ture in postmenopausal osteoporotic women. Maturitas 2003;44:259-65.

Franzén A, Heinegård D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985;232:715-24.

Störk S, Störk C, Angerer P, Kothny W, Schmitt P, Wehr U, et al. Bone sialoprotein is a specific biochemical marker of bone metabolism in postmenopausal women: a random- ized 1-year study. Osteoporos Int 2000;11:790-6.

Tekin Y, Bozdemir AE. Biochemical Markers and Their Affecting Factors in Assessing Osteoporosis. Türk Klinik Biyokimya Derg 2005;3:73-83.

Kalu DN, Cockerham R, Yu BP, Roos BA. Lifelong dietary modulation of calcitonin levels in rats. Endocrinology 1983;113:2010-6.